Holman et al., 2017
This landmark decision by the FDA represents a crucial step in improving patient access to essential medications
Two points from daily work in this space: first, synthetically inflated marketing (fake patients, deepfaked photos) accelerates short-term customer acquisition but creates a persistent trust deficit that's costly to repair once exposed
Participants were randomized to placebo or retatrutide at 1 mg, 4 mg (dose-escalation), 4 mg (no escalation), 8 mg (escalation), 8 mg (no escalation), or 12 mg (escalation) for 48 weeks, following a slow titration protocol
Keep detailed records of any side effects, including timing, severity, and duration
Weeks 5-10: Reduce intensity by 30 to 50 percent